CancerVax

About the offering

CancerVax is a pre-clinical biotechnology company headquartered in Lehi, Utah, developing a Universal Cancer Treatment Platform. The company's core technology is designed to disguise cancer cells to look like well-immunized pathogens — such as measles or chickenpox — thereby tricking the immune system into recognizing and attacking only cancer cells while leaving healthy cells unharmed. The approach uses AI-powered, two-step detection to identify cancer cells both by external and internal markers, then delivers a payload via nanoparticles containing engineered Smart mRNAs that force cancer cells to produce proteins mimicking those of known pathogens. This triggers the immune system's existing memory response to rapidly eliminate the disguised cancer cells. The company has completed successful in-vitro (lab) validation of its Smart mRNA technology in actual cancer cells as of Q1 2025. Development partners include Cytiva and Charles River. CancerVax has filed multiple provisional patent applications with the USPTO and an international PCT application in 2025 to protect its platform. The next milestones include completing therapeutic nanoparticles for targeted cancer indications (Q3 2025) and completing pre-IND animal studies to assess toxicity and efficacy by 2026, though these milestones are not guaranteed. The scientific leadership includes Chief Scientific Officer George Edwin Katibah, PhD (formerly of RAPT Therapeutics and Aduro Biotech, with experience in small molecule STING agonists and personalized cancer neoantigen vaccines), and Principal Scientist Adam Grant, PhD, an inventor of the Universal Cancer Treatment platform and expert computational biologist. CEO Byron Elton has a background primarily in media, marketing, and executive roles across multiple industries, including a prior stint leading a cleantech company. The company previously raised approximately $10.2 million through venture and crowdfunding rounds. The global cancer immunotherapy market is cited as growing from $83 billion in 2023 to a projected $231 billion by 2031 (Statista). Cancer accounts for approximately 10 million deaths per year globally and 1.95 million new U.S. diagnoses in 2023. CancerVax's platform is designed to be indication-agnostic, potentially addressing multiple cancer types. The company notes that FDA clearance is required before any market use and may never be obtained, and all current results are pre-clinical.

FAQ